Dietary soy containing phytoestrogens does not activate the hemostatic system in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 4, 2005, Pages 1936-1941

  Teede, Helena J ^a   Dalais, Fabien S ^a   Kotsopoulos, Dimitra ^a   McGrath, Barry P ^a   Malan, Erica ^b   Gan, T Eng ^b   Peverill, Roger E ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b MONASH MEDICAL CENTRE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 7; CASEIN; D DIMER; FIBRIN; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHYTOESTROGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBIN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ENDOTHELIUM; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; NORMAL HUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOYBEAN;

AGED; DIET; FEMALE; HEMOSTASIS; HUMANS; ISOFLAVONES; LIPIDS; MIDDLE AGED; PEPTIDE FRAGMENTS; PHYTOESTROGENS; POSTMENOPAUSE; PROTEIN PRECURSORS; PROTHROMBIN; SOYBEANS; VON WILLEBRAND FACTOR;

EID: 17844367580     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1428     Document Type: Article

References (56)

1. Setchell KD 1998 Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68:1333S-1346S
2. Anthony MS, Clarkson TB, Bullock BC, Wagner JD 1997 Soy protein versus soy phytoestrogens in the prevention of diet-induced coronary artery atherosclerosis of male cynomolgus monkeys. Arterioscler Thromb Vasc Biol 17:2524-2531
3. Clarkson TB, Anthony MS, Morgan TM 2001 Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 86:41-47
4. Adlercreutz H 1990 Western diet and Western diseases: some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest 201:3-23
5. Nestel PJ, Yamashita T, Sasahara T, Pomeroy S, Dart A, Komesaroff P, Owen A, Abbey M 1997 Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women. Arterioscler Thromb Vasc Biol 17:3392-3398
6. Nestel PJ, Pomeroy S, Kay S, Komesaroff P, Behrsing J, Cameron JD, West L 1999 Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab [Erratum (1999) 84:3647] 84:895-898
7. Teede HJ, Dalais FS, Kotsopoulos D, Liang YL, Davis S, McGrath BP 2001 Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and postmenopausal women. J Clin Endocrinol Metab 86:3053-3060
8. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E 1998 Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605-613
9. Writing Group for the Women's Health Initiative Investigators 2002 Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333
10. Grady D, Wenger NK, Herrington D, Khan S, Furberg C, Hunninghake D, Vittinghoff E, Hulley S 2000 Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 132:689-696
11. Miller J, Chan BKS, Nelson HD 2002 Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US Preventive Services Task Force. Ann Intern Med 136:680-690
12. Caine YG, Bauer KA, Barzegar S, ten Cate H, Sacks FM, Walsh BW, Schiff I, Rosenberg RD 1992 Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 68:392-395
13. Kroon UB, Silfverstolpe G, Tengborn L 1994 The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thromb Haemost 71:420-423
14. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, Virkamaki A, Hovatta O, Hamsten A, Taskinen MR, Yki-Jarvinen H 2001 Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thromb Haemost 85:619-625
15. de Valk-de Roo GW, Stehouwer CDA, Meijer P, Mijatovic V, Kluft C, Kenemans P, Cohen F, Watts S, Netelenbos C 1999 Both raloxifene and estrogen reduce major cardiovascular risk factors in healthy postmenopausal women: a 2-year, placebo-controlled study. Arterioscler Thromb Vasc Biol 19:2993-3000
16. Koh KK, Mincemoyer R, Bui MN, Csako G, Pucino F, Guetta V, Waclawiw M, Cannon 3rd RO 1997 Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336:683-690
17. 1996 Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy: Medical Research Council's General Practice Research Framework. BMJ 312:473-478
18. Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silfverstolpe G 1989 A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost 61:65-69
19. de Valk-de Roo GW, Stehouwer CDA, Emels JJ, Nicolaas-Merkus A, Netelenbos C 2000 Unopposed estrogen increases total plasma factor VII, but not active factor VII: a short-term placebo-controlled study in healthy postmenopausal women. Thromb Haemost 84:968-972
20. Teede HJ, McGrath BP, Smolich JJ, Malan E, Kotsopoulos D, Liang YL, Peverill RE 2000 Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arterioscler Thromb Vasc Biol 20:1404-1409
21. Mannucci PM 1998 von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 18:1359-1362
22. Rabbani LE, Seminario NA, Sciacca RR, Chen HJ, Giardina EG 2002 Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women. J Am Coll Cardiol 40:1991-1999
23. Dalais FS, Rice GE, Wahlqvist ML, Grehan M, Murkies AL, Medley G, Ayton R, Strauss BJ 1998 Effects of dietary phytoestrogens in postmenopausal women. Climacteric 1:124-129
24. Favaloro EJ, Grispo L, Dinale A, Berndt M, Koutts J 1993 von Willebrand's disease: laboratory investigation using an improved functional assay for von Willebrand factor. Pathology 25:152-158
25. Bland JM, Altman DG 1996 Transformations, means, and confidence intervals. BMJ 312:1079
26. Women's Health Initiative Steering Committee 2004 Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291:1701-1712
27. Rock G, Wells P 1997 New concepts in coagulation. Crit Rev Clin Lab Sci 34:475-501
28. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North, WR, Haines AP, Stirling Y, Imeson JD, Thompson SG 1986 Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 2:533-537
29. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE 1997 Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96:1102-1108
30. Cortellaro M, Boschetti C, Cofrancesco E, Zanussi C, Catalano M, de Gaetano G, Gabrielli L, Lombardi B, Specchia G, Tavazzi 1992 The PLAT Study: hemostatic function in relation to atherothrombotic ischemic events in vascular disease patients: principal results. PLAT Study Group. Progetto Lombardo Atero-Trombosi (PLAT) Study Group. Arterioscl Thromb 12:1063-1070
31. Scarabin PY, Aillaud MF, Amouyel P, Evans A, Luc G, Ferrieres J, Arveiler D, Juhan-Vague I 1998 Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction. Thromb Haemost 80:749-756
32. Tracy RP, Bovill EG, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ 1995 Fibrinogen and factor VIII, but not factor VII, are associated with measures of subclinical cardiovascular disease in the elderly. Results from The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 15:1269-1279
33. Cushman M, Yanez D, Psaty BM, Fried LP, Heiss G, Lee M, Polak JF, Savage PJ, Tracy RP 1996 Association of fibrinogen and coagulation factors VII and VIII with cardiovascular risk factors in the elderly: the Cardiovascular Health Study. Cardiovascular Health Study Investigators. Am J Epidemiol 143:665-676
34. Scarabin PY, Bara L, Samama M, Orssaud G 1985 Further evidence that activated factor VII is related to plasma lipids. Br J Haematol 61:186-187
35. Miller GJ, Martin JC, Webster J, Wilkes H, Miller NE, Wilkinson WH, Meade TW 1986 Association between dietary fat intake and plasma factor VII coagulant activity: a predictor of cardiovascular mortality. Atherosclerosis 60:269-277
36. de Sousa JC, Bruckert E, Giral P, Soria C, Chapman J, Truffert J, Dairou F, De Gennes JL, Caen JP 1989 Coagulation factor VII and plasma triglycerides. Decreased catabolism as a possible mechanism of factor VII hyperactivity. Haemostasis 19:125-130
37. de Sousa JC, Soria C, Ayrault-Jarrier M, Pastier D, Bruckert E, Amiral J, Bereziat G, Caen JP 1988 Association between coagulation factors VII and X with triglyceride rich lipoproteins. J Clin Pathol 41:940-944
38. Noto D, Barbagallo CM, Cefalu AB, Cavera G, Sapienza M, Notarbartolo A, Davi G, Averna MR 2002 Factor VII activity is an independent predictor of cardiovascular mortality in elderly women of a Sicilian population: results of an 11-year follow-up. Thromb Haemost 87:206-210
39. Merlini PA, Ardissino D 1997 Laboratory measurement of thrombin activity: what every clinician scientist needs to know. J Thromb Thrombolysis 2:85-92
40. Lip GY, Lowe GD 1995 Fibrin D-dimer: a useful clinical marker of thrombogenesis? Clin Sci 89:205-214
41. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ 1994 Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 90:2236-2240
42. Blann AD, Seigneur M, Steiner M, Boisseau MR, McCollum CN 1997 Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease. Eur J Clin Invest 27:916-921
43. Catto AJ, Carter AM, Barrett JH, Bamford J, Rice PJ, Grant PJ 1997 von-Willebrand factor and factor VIII-c in acute cerebrovascular disease: relationship to stroke subtype and mortality. Thromb Haemost 77:1104-1108
44. Thompson SG, Kienast J, Pyke SDM, Haverkate F, Vandeloo JCW 1995 Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. N Engl J Med 332:635-641
45. Blann AD, Miller JP, McCollum CN 1997 von Willebrand factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidaemia. Atherosclerosis 132:151-156
46. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, Carrie D, Flammang D, Dutoit A, Carayon A, Jardel C, Chevrot M, Bastard JP, Bigonzi F, Thomas D 1998 Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. Circulation 98:294-299
47. Jager A, van Hinsbergh VWM, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CDA 1999 von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn study. Arterioscler Thromb Vasc Biol 19:3071-3078
48. Lieberman EH, Gerhard MD, Uehata A, Walsh BW, Selwyn AP, Ganz P, Yeung AC, Creager MA 1994 Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 121:936-941
49. Dalais FS, Ebeling PR, Kotsopoulos D, McGrath BP, Teede HJ 2003 The effects of soy protein containing isoflavones on lipids and indices of bone resorption in postmenopausal women. Clin Endocrinol (Oxf) 58:704-709
50. Teede HJ, Dalais FS, McGrath BP 2004 Dietary soy containing phytoestrogens does not have detectable estrogenic effects on hepatic protein synthesis in postmenopausal women. Am J Clin Nutr 79:396-401
51. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA 1998 Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139:4252-4263
52. Markiewicz L, Garey J, Adlercreutz H, Gurpide E 1993 In vitro bioassays of non-steroidal phytoestrogens. J Steroid Biochem Mol Biol 45:399-405
53. Anderson JW, Johnstone BM, Cooknewell ME 1995 Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333:276-282
54. Lichtenstein AH, Jalbert SM, Adlercreutz H, Goldin BR, Rasmussen H, Schaefer EJ, Ausman LM 2002 Lipoprotein response to diets high in soy or animal protein with and without isoflavones in moderately hypercholesterolemic subjects. Arterioscler Thromb Vasc Biol 22:1852-1858
55. Simons LA, von Konigsmark M, Simons J, Celermajer DS 2000 Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy postmenopausal women. Am J Cardiol 85:1297-1301
56. Kreijkamp-Kaspers S, Kok L, Grobbee DE, de Haan EH, Aleman A, Lampe JW, van der Schouw YT 2004 Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. JAMA 292:65-74